ANIK Director Granted 14,164 RSUs, Ups Stake to 20,403 Shares

Q: How many Anika Therapeutics (ANIK) shares did William R. Jellison acquire?

14,164 restricted stock units , each representing one common share.

Q: Did the ANIK director sell any shares in this Form 4 filing?

No. The filing reports no disposals ; only an RSU grant at $0 cost.

Q: When will the granted RSUs to William Jellison vest?

They vest in full on the earlier of the 2026 annual meeting or 20 June 2026 .

Q: What is William Jellison鈥檚 total ANIK share ownership after the transaction?

He holds 20,403 shares directly and 2,700 shares indirectly via a trust.

Q: Is this Form 4 filing considered impactful for ANIK investors?

It is generally neutral ; it reflects routine director compensation without buy/sell pressure.

[Form 4] Anika Therapeutics Inc Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Anika Therapeutics (ANIK) 鈥� Form 4 insider filing: Director William R. Jellison reported the grant of 14,164 restricted stock units (RSUs) on 20 June 2025. Each RSU converts to one common share upon vesting, which will occur in full at the earlier of the company鈥檚 2026 annual meeting or 20 June 2026. Following the award, Jellison鈥檚 direct ownership rises to 20,403 common shares; he also holds 2,700 shares indirectly through a revocable trust. No shares were sold or disposed of, and the grant was made at $0 cost, reflecting a routine, equity-based director compensation transaction.

Positive

14,164 RSUs granted to director, lifting direct ownership to 20,403 shares and signaling continued insider alignment with shareholders.

Negative

None.

Insights

TL;DR: Routine Form 4 shows director granted 14,164 RSUs, boosting direct stake to 20,403 shares; no sales鈥攏eutral impact.

This filing reflects Anika鈥檚 standard director equity program. The award modestly increases insider alignment but does not involve open-market buying or selling. With no accompanying operational data or market purchase, the event is informational rather than materially price-moving. Investors may view continued board ownership positively, yet the absolute share count is small relative to ANIK鈥檚 float, limiting valuation impact.

06/24/2025 - 05:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jellison William R

(Last)

(First)

(Middle)

32 WIGGINS AVENUE

(Street)

BEDFORD

01730

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2025		A		14,164⁽¹⁾	A	$0	20,403	D
Common Stock								2,700⁽²⁾	I	Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.

2. Consists of shares transferred by Mr. Jellison to the Amended and Restated William R. Jellison Trust dated July 3, 2018, of which Mr. Jellison is a beneficiary and trustee.

	/s/ William R. Jellison	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many Anika Therapeutics (ANIK) shares did William R. Jellison acquire?

14,164 restricted stock units, each representing one common share.

Did the ANIK director sell any shares in this Form 4 filing?

No. The filing reports no disposals; only an RSU grant at $0 cost.

When will the granted RSUs to William Jellison vest?

They vest in full on the earlier of the 2026 annual meeting or 20 June 2026.

What is William Jellison鈥檚 total ANIK share ownership after the transaction?

He holds 20,403 shares directly and 2,700 shares indirectly via a trust.

Is this Form 4 filing considered impactful for ANIK investors?

It is generally neutral; it reflects routine director compensation without buy/sell pressure.

AG真人官方

[Form 4] Anika Therapeutics Inc Insider Trading Activity

Insights

FAQ

How many Anika Therapeutics (ANIK) shares did William R. Jellison acquire?

Did the ANIK director sell any shares in this Form 4 filing?

When will the granted RSUs to William Jellison vest?

What is William Jellison鈥檚 total ANIK share ownership after the transaction?

Is this Form 4 filing considered impactful for ANIK investors?

NASDAQ:ANIK

ANIK Rankings

ANIK Latest News

ANIK Latest SEC Filings

ANIK Stock Data

AG真人官方

Trending News

[Form 4] Anika Therapeutics Inc Insider Trading Activity

Insights

Financial Analyst neutral

FAQ

How many Anika Therapeutics (ANIK) shares did William R. Jellison acquire?

Did the ANIK director sell any shares in this Form 4 filing?

When will the granted RSUs to William Jellison vest?

What is William Jellison鈥檚 total ANIK share ownership after the transaction?

Is this Form 4 filing considered impactful for ANIK investors?

NASDAQ:ANIK

ANIK Rankings

ANIK Latest News

ANIK Latest SEC Filings

ANIK Stock Data